influenza
virus
belong
famili
orthomyxovirida
categor
four
major
type
b
c
influenza
b
virus
routin
spread
peopl
caus
season
flu
epidem
year
influenza
virus
inflict
million
infect
case
human
anim
everi
year
effect
antivir
essenti
countermeasur
diseas
amantadin
first
synthet
compound
inhibit
influenza
viru
replic
compound
deriv
inhibit
ion
channel
block
migrat
h
ion
interior
viru
particl
process
critic
viru
uncoat
recent
year
howev
influenza
viru
resist
compound
wide
anoth
class
antivir
agent
neuraminidas
na
inhibitor
includ
oseltamivir
zanamivir
peramivir
antivir
agent
inhibit
viral
na
activ
play
import
role
earli
influenza
infect
human
airway
epithelium
viru
oseltamivir
current
common
commerci
antiinfluenza
drug
resist
na
inhibitor
contrari
sever
genomewid
screen
identifi
host
factor
essenti
influenza
viru
altern
aforement
pathogentarget
antivir
grow
effort
devot
block
promot
host
factor
fight
influenza
modul
host
factor
involv
viral
replic
hosttarget
antivir
strategi
may
less
suscept
strain
variat
mutat
exert
select
pressur
target
pathogen
among
host
factor
target
antivir
treatment
vacuolar
atpas
vatpas
promis
target
intercept
viru
entri
host
cell
vatpas
ubiquit
proton
pump
locat
endomembran
system
eukaryot
among
viral
threat
influenza
virus
flavivirus
vaccinia
virus
bornavirus
rhabdovirus
coronavirus
vatpasemedi
endosom
acidif
essenti
cellular
process
viral
inhibit
vatpasemedi
endosom
acidif
may
thu
pave
way
new
antivir
treatment
broad
applic
low
suscept
drugresist
mutat
sever
vatpas
inhibitor
studi
among
plecomacrolid
bafilomycin
first
discov
perhap
notabl
compound
shown
antivir
potenti
clinic
applic
thwart
toxic
addit
vatpas
inhibitor
often
poorli
water
solubl
present
drug
deliveri
challeng
previous
show
diphyllin
new
class
vatpas
effect
block
influenza
viru
nanoformul
show
improv
safeti
effect
inhibit
felin
toward
improv
vatpas
inhibitor
influenza
treatment
herein
prepar
diphyllinload
polymer
nanoparticl
compris
poli
ethylen
glycol
blockpoli
lactidecoglycolid
pegplga
examin
efficaci
influenza
viru
vitro
vivo
parallel
assess
applic
nanoparticlemedi
deliveri
commonli
studi
bafilomycin
particular
nanocarri
chosen
plgabas
polymer
nanoparticl
broadli
adopt
enhanc
deliveri
hydrophob
biodegrad
polym
also
wide
use
fdaapprov
product
therefor
readili
materi
also
shown
induc
littl
innat
immun
studi
physicochem
properti
drug
releas
kinet
diphyllin
bafilomycinload
nanoparticl
examin
cellular
uptak
nanoparticl
assess
two
differ
influenza
viruspermiss
cell
line
includ
mh
adult
retin
pigment
epitheli
cell
demonstr
nanoparticul
vatpas
inhibitor
less
cytotox
free
drug
compound
reduc
influenza
viral
infect
vitro
use
diphyllin
nanoparticl
also
show
hosttarget
treatment
appli
multipl
strain
influenza
virus
success
reduc
diseas
sever
mous
model
influenza
viru
infect
highlight
potenti
nanoparticul
vatpas
inhibitor
antivir
develop
mdck
madin
darbi
canin
kidney
cell
maintain
dmem
supplement
fb
penicillinstreptomycinamphotericin
b
psa
mh
murin
alveolar
macrophag
am
cell
maintain
atccformul
medium
supplement
final
concentr
mm
fb
final
concentr
psa
influenza
viru
infect
mdck
mh
cell
infect
medium
rpmi
contain
bsa
mm
psa
chloromethyl
ketonetr
trypsin
use
cell
maintain
supplement
fb
psa
cell
purchas
bioresourc
collect
research
center
bcrc
hsinchu
taiwan
cultur
reagent
cell
cultur
purchas
invitrogen
influenza
viru
apuerto
kindli
provid
professor
shinru
shih
chang
gung
univers
kindli
provid
professor
hungchih
yang
nation
taiwan
univers
virus
propag
allanto
caviti
embryon
chicken
egg
viral
titer
determin
diphyllin
sigmaaldrich
co
st
loui
mo
usa
bafilomycin
lc
laboratori
woburn
usa
encapsul
pegfunction
plga
nanoparticl
use
oilinwat
emuls
techniqu
briefli
mg
diphyllin
bafilomycin
dissolv
mg
pegplga
diblock
copolym
sigma
ml
chloroform
honeywel
intern
inc
morri
plain
nj
usa
solut
subsequ
ad
ml
mm
phosphat
buffer
ph
dispers
use
probe
sonic
minut
second
power
form
singl
emuls
follow
sonic
emuls
place
insid
fume
hood
gentl
stir
rpm
evapor
chloroform
follow
hour
solvent
evapor
result
nanoparticl
collect
wash
ml
phosphat
buffer
ultracentrifug
g
minut
nanoparticl
resuspend
sucros
subsequ
character
empti
pegplga
nanoparticl
also
prepar
control
studi
prepar
fluoresc
label
nanoparticl
mg
fluoresc
dye
salt
nm
thermo
fisher
scientif
waltham
usa
ad
solvent
phase
singl
emuls
process
tem
observ
neg
stain
appli
first
nanoparticl
ad
glowdischarg
grid
droplet
place
grid
second
drop
appli
grid
wash
away
excess
nanoparticl
subsequ
grid
stain
uranyl
acet
second
stain
subsequ
remov
wick
piec
filter
paper
nanoparticl
size
zeta
potenti
determin
dl
use
malvern
zetas
nano
zs
malvern
instrument
malvern
uk
follow
manufactur
instruct
measur
made
ml
nanoparticl
mgml
water
fold
capillari
zeta
cell
malvern
panalyt
content
diphyllin
bafilomycin
pegplga
nanoparticl
quantifi
hplc
agil
technolog
santa
clara
ca
usa
seri
briefli
nanoparticl
load
diphyllin
bafilomycin
dissolv
aceton
airdri
sampl
dissolv
mobil
phase
solvent
diphyllin
acetonitrilebafilomycin
acetonitril
filter
prior
hplc
ascenti
column
equip
mobil
phase
optim
detect
wavelength
nm
column
temperatur
serial
dilut
sampl
diphyllin
mgml
bafilomycin
mgml
dissolv
mobil
phase
solvent
prepar
standard
hplc
analysi
drug
releas
kinet
determin
either
phosphat
buffer
mm
mm
ph
acet
buffer
acet
acid
sodium
acet
ph
set
dialysi
tube
slidealyz
mini
dialysi
devic
load
drugload
nanoparticl
contain
mg
diphyllin
bafilomycin
tube
place
tank
phosphat
buffer
acet
buffer
drugload
nanoparticl
harvest
dialysi
tube
minut
hour
hour
hour
hour
hour
hour
hour
nanoparticl
sampl
dissolv
aceton
drug
content
analyz
hplc
mh
cell
cell
seed
chamber
slide
day
prior
experi
cell
treat
didlabel
diphyllin
bafilomycin
nanoparticl
mgml
cultur
media
hour
incub
cultur
supernat
remov
cell
wash
pb
buffer
untreat
cell
use
control
cell
fix
use
formalin
vv
water
cellular
nuclei
stain
dapi
fluoresc
microscopi
olympu
corpor
tokyo
japan
use
examin
cellular
uptak
fluoresc
nanoparticl
evalu
cytotox
concentr
mh
cell
grown
clear
polystyren
micropl
densiti
cell
per
well
day
prior
experi
free
drug
drugload
nanoparticl
twofold
serial
dilut
cell
media
ad
cell
monolay
four
replic
hour
incub
alamarblu
reagent
thermo
fisher
scientif
ad
well
evalu
cellular
viabil
absorb
valu
measur
nm
refer
wavelength
nm
free
drug
drugload
nanoparticl
analyz
use
prism
graphpad
softwar
inc
la
jolla
ca
usa
cpe
inhibit
assay
use
determin
free
drug
drugload
nanoparticl
concentr
drug
show
inhibit
virusinduc
cpe
influenza
viru
briefli
mh
cell
seed
micropl
cellswel
day
experi
free
drug
drugload
nanoparticl
infect
medium
ad
mh
cell
hour
infect
hour
incub
cell
infect
influenza
viru
multipl
infect
moi
infect
virus
remov
free
drug
drugload
nanoparticl
cell
medium
ad
back
cell
hour
cellular
viabil
examin
alamarblu
assay
free
drug
drugload
nanoparticl
determin
use
prism
graphpad
evalu
activ
free
drug
drug
nanoparticl
block
viral
replic
mh
cell
cultur
use
cell
pretreat
hour
free
drug
drugload
nanoparticl
infect
influenza
viru
hour
infect
virus
remov
cell
wash
subsequ
fresh
cell
media
contain
drugload
nanoparticl
ad
cell
hour
incub
supernat
harvest
assess
viral
titer
antiinfluenza
efficaci
studi
perform
mice
group
six
femal
balbc
mice
purchas
nation
laboratori
anim
center
taipei
taiwan
mice
infect
nonleth
dose
pfu
plaqueform
unit
equal
lethal
dose
pfu
equal
influenza
viru
via
intranas
administr
light
anesthesia
zoletil
mgkg
right
viru
infect
mice
intraven
inject
diphyllin
nanoparticl
contain
diphyllin
day
mice
receiv
empti
pegplga
nanoparticl
set
control
group
follow
viru
infect
mice
monitor
daili
weight
chang
surviv
nonleth
dose
infect
experi
two
mice
group
sacrif
day
postvir
infect
lung
mice
harvest
homogen
infect
medium
viral
load
determin
quantit
rtpcr
qrtpcr
describ
anim
experi
studi
conduct
accord
guidelin
institut
anim
care
use
committe
iacuc
nation
taiwan
univers
approv
number
tissu
cultur
infect
dose
assay
mdck
cell
seed
micropl
cellswel
day
experi
first
growth
media
remov
cell
wash
pb
buffer
sampl
tenfold
serial
dilut
infect
medium
dilut
sampl
ad
cell
incub
hour
infect
media
remov
cell
wash
subsequ
fresh
viru
media
ad
well
hour
incub
supernat
harvest
perform
direct
hemagglutin
assay
spot
assay
chicken
rbc
viral
titer
determin
reed
muench
plaqu
assay
mdck
cell
seed
plate
obtain
confluenc
cellswel
day
experi
first
growth
medium
remov
cell
wash
pb
buffer
sampl
tenfold
serial
dilut
infect
medium
dilut
sampl
ad
cell
incub
hour
gentl
shake
infect
cultur
media
remov
cell
wash
pb
two
millilit
agaros
infect
medium
ad
well
hour
incub
cell
fix
formalin
minut
agaros
overlay
remov
run
water
cell
stain
crystal
violet
room
temperatur
minut
dri
viral
plaqu
count
viral
titer
determin
viral
rna
quantif
lung
mice
qrtpcr
perform
previous
modif
briefli
viral
rna
extract
use
viral
nucleic
acid
extract
kit
geneaid
biotech
ltd
taipei
taiwan
cdna
synthes
use
quantinova
revers
transcript
kit
qiagen
nv
venlo
netherland
follow
manufactur
instruct
qpcr
reaction
mixtur
prepar
mix
nm
primer
primer
nm
famlabel
probe
integr
dna
technolog
primetim
gene
express
mastermix
integr
dna
technolog
cdna
cycl
protocol
thermal
cycler
consist
minut
preheat
follow
cycl
second
denatur
minut
primer
anneal
extens
cfx
connect
biorad
laboratori
inc
hercul
ca
usa
two
microlit
plasmid
dna
contain
variou
copi
number
matrix
protein
gene
influenza
viru
use
standard
curv
construct
qrtpcr
viral
load
quantif
two
replic
perform
sampl
standard
data
analyz
unpair
ttest
anova
follow
dunnett
multipl
comparison
test
use
prism
graphpad
pvalu
consid
statist
signific
composit
diphyllin
nanoparticl
illustr
figur
use
dl
diphyllinload
nanoparticl
studi
show
zaverag
diamet
nm
figur
result
diphyllin
nanoparticl
show
uniformli
spheric
shape
visual
tem
figur
quantif
diphyllin
load
pegplga
nanoparticl
determin
hplc
standard
curv
construct
serial
dilut
sampl
diphyllin
mgml
separ
correspond
area
valu
mau
second
figur
peak
detect
diphyllin
appear
minut
figur
refer
standard
curv
content
diphyllin
nanoparticl
batch
determin
studi
averag
load
effici
diphyllin
schemat
present
bafilomycinload
nanoparticl
illustr
figur
use
dl
bafilomycinload
nanoparticl
use
studi
zaverag
diamet
nm
figur
result
bafilomcycinload
nanoparticl
show
uniformli
spheric
shape
visual
tem
figur
quantif
bafilomycin
load
pegplga
nanoparticl
determin
hplc
standard
curv
construct
serial
dilut
sampl
bafilomycin
mgml
separ
correspond
area
valu
mau
second
figur
peak
detect
bafilomycin
appear
minut
figur
refer
standard
curv
content
bafilomycin
nanoparticl
batch
determin
studi
load
effici
bafilomycin
nanoparticul
vatpas
inhibitor
show
similar
physicochem
properti
interestingli
bafilomycin
encapsul
much
effici
diphyllin
may
attribut
bafilomycin
lower
water
solubl
drug
releas
studi
perform
phosphat
buffer
ph
acet
buffer
ph
simul
extracellular
endosom
condit
respect
diphyllin
nanoparticl
littl
diphyllin
releas
nanoparticl
first
hour
hour
diphyllin
releas
acid
buffer
diphyllin
releas
phosphat
buffer
hour
diphyllin
releas
acid
buffer
diphyllin
releas
phosphat
buffer
figur
overal
diphyllin
releas
nanoparticl
larg
similar
two
ph
valu
observ
period
bafilomycinload
nanoparticl
bafilomycin
releas
acid
buffer
bafilomycin
releas
phosphat
buffer
first
hour
hour
bafilomycin
releas
acid
buffer
bafilomycin
releas
phosphat
buffer
hour
bafilomycin
releas
acid
buffer
bafilomycin
releas
phosphat
buffer
figur
bafilomycin
releas
acceler
ph
compar
ph
overal
diphyllin
bafilomycin
nanoparticl
exhibit
sustain
drug
releas
profil
hour
verifi
nanocarri
effici
deliv
drug
payload
intracellularli
mh
cell
cell
treat
fluoresc
didlabel
diphyllin
bafilomycin
nanoparticl
fluoresc
signal
examin
magnif
fluoresc
microscop
nucleu
stain
dapi
shown
blue
nanoparticl
shown
red
untreat
control
cell
reveal
fluoresc
mh
cell
took
nanoparticl
effici
figur
indic
success
intracellular
drug
deliveri
nanoparticl
assess
safeti
drugload
nanoparticl
standard
alamarblu
assay
use
determin
cytotox
free
drug
drugload
nanoparticl
mh
cell
follow
incub
valu
free
diphyllin
diphyllin
nanoparticl
respect
figur
improv
safeti
follow
nanoparticl
encapsul
also
observ
bafilomycin
fourfold
reduct
cytotox
observ
nanoformul
valu
free
bafilomycin
bafilomycin
nanoparticl
nm
nm
respect
figur
result
indic
improv
safeti
achiev
nanoparticul
diphyllin
bafilomycin
may
facilit
sustain
releas
enhanc
drug
local
endolysosom
compart
reduc
side
effect
free
drug
drugload
influenza
viru
determin
cpe
inhibit
assay
mh
cell
result
show
free
diphyllin
wherea
diphyllin
nanoparticl
figur
demonstr
improv
antivir
activ
nanoformul
calcul
therapeut
index
ti
yield
valu
free
diphyllin
diphyllin
nanoparticl
respect
similarli
antivir
activ
free
bafilomycin
bafilomycin
nanoparticl
influenza
viru
also
compar
mh
cell
result
show
free
bafilomycin
nm
wherea
bafilomycin
nanoparticl
nm
figur
benefit
nanoparticl
deliveri
less
pronounc
bafilomycin
may
attribut
strong
potenc
compound
calcul
ti
yield
valu
free
bafilomycin
bafilomycin
nanoparticl
respect
compar
free
drug
nanoparticul
vatpas
inhibitor
exhibit
lower
cytotox
greater
antivir
activ
improv
therapeut
index
diphyllin
bafilomycin
approxim
three
fivefold
respect
compar
assess
viral
inhibitori
effect
free
nanoparticul
vatpas
inhibitor
yield
progeni
viru
upon
nanoparticul
diphyllin
bafilomycin
treatment
mh
cell
examin
result
show
diphyllin
nanoparticl
induc
dosedepend
inhibit
infect
group
treat
diphyllin
nanoparticl
signific
decreas
viral
titer
compar
untreat
free
diphyllintr
group
figur
demonstr
nanoparticlemedi
deliveri
could
enhanc
antiinfluenza
activ
vatpas
inhibitor
examin
nanoparticl
activ
influenza
viru
assess
potenti
broadspectrum
antivir
shown
figur
mean
viral
pfu
titer
group
treat
diphyllin
nanoparticl
pfuml
wherea
mean
viru
titer
untreat
medium
group
pfuml
valid
diphyllin
nanoparticl
appli
multipl
strain
influenza
virus
parallel
antiinfluenza
activ
bafilomycin
nanoparticl
also
assess
similarli
mh
cell
pretreat
bafilomycin
nanoparticl
variou
concentr
infect
influenza
viru
infect
viru
remov
bafilomycin
nanoparticl
ad
cell
hour
incub
supernat
harvest
determin
viral
titer
result
show
bafilomycin
nanoparticl
exhibit
dosedepend
inhibit
viru
infect
viral
titer
group
treat
nm
bafilomycin
group
treat
nm
bafilomycin
group
significantli
reduc
viral
titer
compar
medium
control
group
figur
demonstr
nanoparticl
deliveri
strategi
appli
differ
type
vatpas
inhibitor
antivir
applic
diphyllin
nanoparticl
previous
shown
well
toler
examin
applic
nanoparticul
vatpas
inhibitor
influenza
treatment
vivo
mous
model
influenza
infect
use
mice
inocul
intranas
nonleth
dose
viru
intraven
treat
diphyllin
nanoparticl
equival
diphyllin
empti
nanoparticl
equival
polym
content
daili
day
figur
mice
subsequ
monitor
weight
loss
lung
viral
load
studi
control
mice
progress
lost
weight
day
contrast
mice
treat
diphyllin
nanoparticl
reduc
bodi
weight
loss
figur
lung
mice
harvest
viral
rna
assess
day
postinfect
although
statist
signific
reach
diphyllin
nanoparticl
treatment
allevi
viral
load
lung
mice
figur
evalu
efficaci
diphyllin
nanoparticl
lethal
infect
viru
figur
compar
control
group
mice
receiv
singl
treatment
diphyllin
nanoparticl
show
reduc
weight
loss
figur
improv
surviv
rate
upon
termin
studi
figur
contrast
empti
nanoparticlereceiv
mice
succumb
viru
infect
within
day
postinfect
vivo
data
collect
suggest
diphyllin
nanoparticl
abl
reduc
diseas
sever
enhanc
surviv
outcom
mirror
antiinfluenza
activ
observ
vitro
investig
emerg
drugresist
viral
strain
antiinfluenza
studi
begin
focu
hosttarget
therapi
studi
util
two
vatpas
inhibitor
diphyllin
bafilomycin
interfer
endosom
acidif
critic
process
influenza
viru
replic
previou
studi
also
reli
inhibit
endosom
acidif
fight
influenza
viru
use
altern
vatpas
inhibitor
saliphenylhalamid
saliph
sever
older
vatpas
inhibitor
concanamycin
archazolid
b
studi
efficaci
influenza
viru
vitro
aforement
vatpas
inhibitor
shown
inhibit
endosom
acidif
influenza
viru
replic
vitro
demonstr
broadspectrum
treatment
potenti
drug
deliveri
drug
toxic
two
critic
factor
undermin
therapeut
potenti
candid
compound
overcom
challeng
nanoparticul
drug
deliveri
system
offer
sever
advantag
term
improv
drug
deliveri
reduc
toxic
compar
tradit
form
drug
studi
diphyllin
bafilomycin
hydrophob
compound
possess
cytotox
concern
improv
applic
compound
adopt
pegplgabas
polymer
nanoparticl
system
readili
encapsul
waterinsolubl
molecul
hydrophob
polymer
core
nanocarri
facilit
deliveri
diphyllin
bafilomycin
absenc
organ
solvent
steadi
drug
pharmacokinet
pegmedi
long
circul
sustain
drug
upon
nanoparticl
encapsul
water
solubl
drug
improv
cytotox
reduc
moreov
diphyllin
bafilomycin
show
sustain
releas
profil
advantag
toward
improv
drug
pharmacokinet
previou
report
show
diphyllin
nanoparticl
could
enhanc
compound
efficaci
felin
studi
verifi
nanocarri
effect
influenza
viru
studi
shown
similar
benefit
upon
nanoparticl
encapsul
antivir
instanc
saliph
poorli
solubl
compound
encapsul
porou
silicon
nanoparticl
salipheload
porou
silicon
nanoparticl
improv
compound
water
solubl
reduc
side
effect
howev
saliph
nanoparticl
vivo
efficaci
remain
anoth
exampl
hivi
integras
strand
transfer
inhibitor
dolutegravir
encapsul
nanoparticl
polym
nanoparticl
encapsul
drug
could
better
target
macrophag
attenu
viral
replic
spread
viru
result
echo
present
find
nanoparticul
drug
deliveri
system
use
tool
improv
deliveri
vatpas
inhibitor
am
suscept
influenza
viru
play
protect
role
immun
deplet
am
influenza
infect
promot
secondari
bacteri
superinfect
therebi
increas
sever
mh
cell
cell
line
deriv
balbc
mice
retain
mani
properti
use
vitro
model
influenza
data
two
nanoparticul
vatpas
inhibitor
exhibit
potent
antiinfluenza
activ
am
vitro
effect
respiratori
epitheli
cell
rpmi
cell
recent
develop
welldifferenti
airway
epithelium
cultur
interest
futur
investig
beyond
respiratori
tract
tissu
sever
ocular
epitheli
cell
shown
support
product
replic
avian
human
influenza
virus
vitro
ex
influenza
viru
isol
eye
infect
studi
cell
retin
epitheli
cell
line
shown
uptak
drug
nanoparticl
effici
suggest
potenti
applic
vatpasetarget
treatment
viral
infect
eye
studi
may
extend
valid
antivir
effect
diphyllin
bafilomycin
nanoparticl
cell
major
advantag
behind
antivir
approach
base
interfer
promot
host
factor
broadspectrum
antivir
activ
less
suscept
drug
resist
mutat
numer
cellular
pathway
essenti
viral
replic
hostdirect
therapeut
potenti
reduc
viral
replic
diminish
harm
inflammatori
sever
hosttarget
antivir
current
investig
latephas
clinic
addit
vatpas
inhibitor
host
factor
may
contempl
improv
design
antivir
nanoparticl
given
recent
rise
immunomodulatori
nanoparticl
antivir
nanoparticl
may
also
incorpor
innat
immun
modul
enhanc
treatment
potenc
studi
first
time
demonstr
therapeut
promis
nanoparticul
vatpas
inhibitor
mous
model
influenza
viru
infect
use
diphyllin
nanoparticl
reduc
sever
influenza
improv
surviv
outcom
mous
model
infect
investig
prophylact
therapeut
efficaci
warrant
futur
studi
drug
dose
administr
rout
optim
nasal
epithelium
serv
portal
entri
influenza
local
intranas
administr
antivir
nanoparticl
may
consid
moreov
accumul
line
evid
show
drug
combin
significantli
improv
antiinfluenza
efficaci
mani
exist
previous
show
combin
diphyllin
oseltamivir
diphyllin
amantadin
demonstr
enhanc
antivir
effect
cell
sever
random
control
trial
set
test
safeti
efficaci
variou
combin
influenza
recent
exampl
administr
protectin
hosttarget
therapeut
candid
show
protect
lethal
influenza
viral
challeng
combin
peramivir
pathogentarget
antivir
drug
treatment
protectin
peramivir
alon
provid
partial
protect
light
success
combinatori
treatment
simultan
deliveri
multipl
synergist
antivir
drug
singl
nanocarri
may
design
versatil
nanotechnolog
platform
furthermor
target
specif
hostdirect
therapeut
may
enhanc
surfac
modif
drugload
instanc
influenza
viru
target
nanoparticl
recent
demonstr
cell
membraneco
strategi
may
appli
facilit
antivir
drug
target
futur
studi
warrant
valid
improv
nanoparticlebas
antivir
treatment
summari
success
construct
character
diphyllinload
nanoparticl
bafilomycinload
nanoparticl
nanoparticl
achiev
sustain
releas
beyond
hour
effici
taken
multipl
type
cell
line
cellbas
assay
nanoformul
diphyllin
bafilomycin
reveal
enhanc
safeti
viral
inhibitori
activ
free
drug
moreov
diphyllinload
nanoparticl
show
broadspectrum
activ
two
subtyp
viru
infect
select
diphyllin
vivo
studi
diphyllinload
nanoparticl
well
toler
mice
reduc
weight
loss
lung
viral
load
influenza
viru
infect
nanoparticl
also
improv
mice
surviv
follow
lethal
influenza
viral
challeng
collect
work
highlight
nanoformul
vatpas
inhibitor
potenti
hosttarget
treatment
influenza
continu
develop
nanoformul
warrant
